Skip Navigation

Annals of Oncology 2007 18(Supplement 10):x20-x24; doi:10.1093/annonc/mdm410
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Judson, I
Right arrow Articles by Demetri, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Judson, I
Right arrow Articles by Demetri, G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

symposium articles

Advances in the treatment of gastrointestinal stromal tumours

I Judson1,* and G Demetri2

1 Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust, Sutton, UK
2 Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

* Correspondence to: I. Judson, Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel: +44-208-722-4303; Fax: +44-208-642-7979; E-mail: ian.judson{at}icr.ac.uk

Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease progression in many patients. Nevertheless, primary and secondary (acquired) resistance to imatinib is a substantial problem in routine clinical practice. Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that was approved for the treatment of imatinib-resistant or -intolerant GIST. In the pivotal phase III study, sunitinib provided substantial clinical benefits including disease control and superior survival versus placebo as second-line treatment. Treatment with sunitinib was reasonably well tolerated. The availability of sunitinib represents an important clinical advance in GIST management, providing physicians and patients with an effective therapy when resistance to imatinib develops.

Key words: GIST, imatinib, KIT, PDGFR, sunitinib


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.